ORIGINAL ARTICLE
Correlation of programmed death cell ligand-1 expression in non-small cell lung cancer between small biopsy and surgical specimens
1
Medical Faculty of The Military Medical Academy, University of Defence, Belgrade, Serbia
2
Institute of Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia
3
Faculty of Medicine, Novi Sad, Serbia
These authors had equal contribution to this work
Submission date: 2025-03-15
Final revision date: 2026-02-09
Acceptance date: 2026-03-17
Publication date: 2026-06-08
Corresponding author
Jelena Aleksić
Medical Faculty of The Military Medical Academy University of Defence Belgrade, Serbia
Medical Faculty of The Military Medical Academy University of Defence Belgrade, Serbia
Pol J Pathol 2026;77(1):44-52
KEYWORDS
TOPICS
ABSTRACT
Immunotherapy with programmed death cell ligand-1 (PD-L1) antibodies is an essential treatment for non-small cell lung cancer (NSCLC), and immunohistochemical assessment of PD-L1 expression is required for therapeutic stratification.
This study analyzed PD-L1 expression in paired small biopsy and surgical specimens from patients with NSCLC, including adenocarcinoma and squamous cell carcinoma. Associations with the histological type, pathological stage, and clinicopathological parameters were evaluated, and concordance between biopsies and corresponding resections was assessed. A five-year retrospective-prospective study included 102 patients. Programmed death cell ligand-1 expression was determined by immunohistochemistry using monoclonal antibody clone 28-8.
Membranous staining in more than 1% of tumour cells was considered positive. No statistically significant difference in PD-L1 expression was found between small biopsy and surgical specimens (p = 0.790). Expression showed no significant association with patient age or gender. A significant association was observed between PD-L1 expression and smoking status in both specimen types (p = 0.012 and p = 0.019). Programmed death cell ligand-1 expression was not significantly related to the T descriptor (p = 0.548) or N descriptor (p = 0.617).
A statistically significant correlation was identified between PD-L1 positivity and disease stage (p = 0.012). The high concordance of PD-L1 expression between biopsy and surgical material supports use of biopsies for immunotherapy planning in ineligible patients and confirms reliability of resection specimens for adjuvant treatment decisions.
REFERENCES (50)
1.
Dela Cruz SC, Tanoue TL, Matthay AR. Lung cancer: epidemiology, etiology and prevention. Clin Chest Med 2011; 32: 605-644.
2.
Cheng TD, Cramb MS, Baade DP, Youlden DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol 2016; 11: 1653-1671.
3.
Jung CY, Antonia SJ. Tumor immunology and immune checkpoint inhibitors in non-small cell lung cancer. Tuberc Resp Dis 2018; 81: 29-41.
4.
Roach C, Zhang N, Corigliano E, Jansson M, Toland G, Pon- to G, et al. Development of a companion diagnostic PD-L1 immunohistochemistry assay for pembrolizumab therapy in non-small-cell lung cancer. Appl Immunohistochem Mol Morphol 2016; 24: 392-397.
5.
Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch FR, et al. Programmed death-ligand 1 immunohistochemistry in lung cancer: in what state is this art. J Thorac Oncol 2015; 10: 985-989.
6.
Yu H, Boyle AT, Zhou C, Rimm DL, Hirsch FR. PD-L1 expression in lung cancer. J Thorac Oncol 2017; 12: 157-159.
7.
Sakaguchi T, Iketani A, Ito K, Nishii Y, Katsuta K, Hataji O. Comparison of PD-L1 expression between preoperative biopsy specimens and surgical specimens in non-small cell lung cancer. Cancers (Basel) 2025; 17: 398.
8.
Shigeta N, Yokose T, Murakami S, Isaka T, Shinada K, Yoshio-ka E, et al. Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with “adenocarcinoma” and “non-small cell carcinoma favor adenocarcinoma”. Thorac Cancer 2024; 15: 458-465.
9.
McLaughlin J, Han G, Schalper KA, Carvajal-Hausdorf D, Pelekanou V, Rehman J, et al. Quantitative assessment of the heterogeneity of PD-L1 expression in non-small-cell lung cancer. JAMA Oncol 2015; 2: 1-9.
10.
Gerdes MJ, Sevinsky CJ, Sood A, Adak S, Bello MO, Bordwell A, et al. Highly multiplexed single-cell analysis of formalin- fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci U S A 2013; 110: 11982-1197.
11.
Gompelmann D, Sinn K, Brugger J, Bernitzky D, Mosleh B, Prosch H, et al. Correlation of PD-L1 expression on tumour cells between diagnostic biopsies and surgical specimens of lung cancer in real life with respect to biopsy techniques and neoadjuvant treatment. J Cancer Res Clin Oncol 2023; 149: 1747-1754.
12.
Tsao MS, Kerr MK, Dacic S, Yatabe Y, Hirsch FR. IASLC atlas of PD-L1 immunohistochemistry testing in lung cancer. 1st ed. North Fort Myers: Editorial RX Press 2017.
13.
Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14: 847-856.
14.
Hendry S, Byrne JD, Wright MG, Young RJ, Sturrock S, Cooper WA, et al. Comparison of four PD-L1 immunohisto chemical assays in lung cancer. J Thorac Oncol 2017; 12: 367-376.
15.
Thunnissen E, De Langen JA, Smit FE. PD-L1 IHC in NSCLC with a global and methodological perspective. Lung Cancer 2017; 113: 102-105.
16.
Katoda K, Nitadori JI, Woo MK, Sima CS, Finley DJ, Rusch VW, et al. Comprehensive pathological analyses in lung squamous cell carcinoma: single cell invasion, nuclear diameter and tumor budding are independent prognostic factors for worse outcomes. J Thorac Oncol 2014; 9: 1126-1139.
17.
Zhang M, Li G, Wang Y, Wang Y, Zhao S, Haihong P, et al. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep 2017; 7: 10255.
18.
Jin Y, Shen X, Pan Y, Zheng Q, Chen H, Hu H, et al. Correlation between PD-L1 expression and clinicopathological characteristics of non-small cell lung cancer: a real-world study of a large Chinese cohort. J Thorac Dis 2019; 11: 4591-4601.
19.
Huynh GT, Morales-Oyarvide V, Campo JM, Gainor JF, Bozkurtlar E, Uruga H, et al. Programmed cell death ligand 1 expression in resected lung adenocarcinomas: association with immune microenvironment. J Thorac Oncol 2016; 11: 1869-1878.
20.
Chang YC, Hsu PC, Li SH, Weng SH, KuoCH, Yang TY, et al. The prevalence of PD-L1 expression in lung cancer. Clin Oncol 2019; 4: 1591.
21.
Takada K, Okamoto T, Shoji F, Shimokawa M, Akamine T, Takamori S, et al. Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma. J Thorac Oncol 2016; 11: 1879-1890.
22.
Sun JM, Zhou W, Choi YL, Choi SJ, Kim SE, Wang Z, et al. Prognostic significance of PD-L1 in patients with non-small cell lung cancer: a large cohort study of surgically resected casses. J Thorac Oncol 2016; 11: 1003-1011.
23.
Rangachari D, Vanderlann AP, Shea M, Le X, Huberman MS, Kobayashi SS, et al. Correlation between classic driver oncogene mutations in EGFR, ALK or ROS1 and 22C3 PD-L1 ≥ 50% expression in lung adenocarcinoma. J Thorac Oncol 2017; 12: 878-883.
24.
Tang Y, Fang S, Zhang Y, Hong S, Kang S, Yan Y, et al. The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. Oncotarget 2015; 6: 14209-14219.
25.
Heymann JJ, Bulman WA, Swinarski D, Pagan CA, Crapanzano JP, Haghighi M, et al. PD-L1 expression in non-small cell lung carcinoma: comparison among cytology, small biopsy, and surgical resection specimens. Cancer Cytopathol 2017; 125: 896-907.
26.
Munari E, Zamboni G, Lunardi G, Marchionni L, Marconi M, Sommaggio M, et al. PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization. J Thorac Oncol 2018; 13: 1113-1120.
27.
Pawelczyk K, Piotrowska A, Ciesielska U, Jablonska K, Gletzel- Plucinska N, Grzegrzolka J, et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int J Mol Sci 2019; 20: 824.
28.
Uruga H, Bozkurtlar E, Huynh GT, Muzikansky A, Goto Y, Gomez-Caraballo M, et al. Programmed cell death ligand (PD-L1) expression in stage II and III lung adenocarcinomas and nodal metastases. J Thorac Oncol 2016; 12: 458-466.
29.
Wu S, Shi X, Sun J, Liu Y, Luo Y, Liang Z, et al. The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma. Oncotarget 2017; 8: 16421-1649.
30.
Driver RB, Miller AR, Miller T, Deavers M, Gorman B, Mody D, et al. Programmed death ligand-1 (PD-L1) expression in either tumor cells or tumor infiltrating immune cells correlates with solid and high-grade lung adenocarcinomas. Arch Pathol Lab Med 2017; 141: 1529-1532.
31.
Petrelli F, Maltese M, Tomasello G, Conti B, Borgonovo K, Cabiddu M, et al. Clinical and molecular predictors of PD-L1 expression in non-small cell lung cancer: a systematic review and meta-analysis. Clin Lung Cancer 2018; 19: 315-322.
32.
D’Incecco A, Andreozzi M, Ludovini V, Rossi E, Capodanno A, Landi L, et al. PD-1 and PD-L1 expression in molecularly selected non-small cell lung cancer patients. Br J Cancer 2015; 112: 95-102.
33.
Kitazono S, Fujiwara Y, Tsuta K, Utsumi H, Kanda S, Horinouchi H, et al. Reliability of small biopsy samples compared with resected specimens for the determination of programmed death-ligand 1 expression in non-small-cell lung cancer. Clin Lung Cancer 2015; 16: 385-390.
34.
Yang H, Shi J, Lin D, Li X, Zhao C, Wang Q, et al. Prognostic value of PD-L1 expression in combination with CD8+ TILs density in patients with surgically resected non-small cell lung cancer. Cancer Med 2018; 7: 32-45.
35.
Velcheti V, Schalper KA, Carvajal DE, Anagnostou VK, Syri-gos KN, Sznol M, et al. Programmed death ligand-1 expression in non-small cell lung cancer. Lab Invest 2014; 94: 107-116.
36.
Gainor FJ, Rizvi H, Jimenez Aguilar EJ, Skoulidis F, Yeap BY, Naidoo J, et al. Clinical activity of programmed cell death 1 (PD-L1) blockade in never, light and heavy smokers with non-small-cell lung cancer and PD-L1 expression. Ann Oncol 2020; 31: 404-411.
37.
Hirai A, Yoneda K, Shimajiri S, Kuroda K, Hanagiri T, Fujino Y, et al. Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung. J Thorac Cardiovasc Surg 2018; 155: 382-392.
38.
Yvorel V, Patoir A, Casteillo F, Tissot C, Fournel P, Stachowicz ML, et al. PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. PLoS One 2017; 12: e0180346.
39.
Ameratunga M, Asadi K, Lin X, Walkiewicz M, Murone C, Knight S, et al. PD-L1 and tumor infiltrating lymphocytes as prognostic markers in resected NSCLC. PloS One 2016; 11: e0153954.
40.
Wu Y, Ju Q, Qian B, Zhang F, Shi H. The effectiveness of PD-L1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages. Oncotarget 2018; 9: 7942-7948.
41.
Li H, Xu Y, Wan B, Song Y, Zhan P, Hu Y, et al. The clinicopathological and prognostic significance of PD-L1 expression assessed by immunohistochemistry in lung cancer: a meta- analysis of 50 studies with 11383 patients. Trasnl Lung Cancer Res 2019; 8: 429-449.
42.
Calles A, Liao X, Sholl L, Rodig SJ, Freeman GJ, Butaney M, et al. Expression of PD-L1 and its ligands, PD-L1 and PD-L2 in smokers and never smokers with KRAS mutant lung cancer. J Thorac Oncol 2015; 10: 1726-1735.
43.
Schmidt LH, Kummel A, Gorlich D, Mohr M, Bröckling S, Mikesch JH, et al. PD-1 and PD-L1 expression in NSCLC indicate a favorable prognosis in defined subgroups. PloS One 2015; 10: e0136023.
44.
Molina RJ, Yang P, Cassivi SD, Schild SE, Adjei AA, et al. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008; 83: 584-594.
45.
Kato Y, Kashima J, Watanabe K, Yomota M, Zenke Y, Oku-ma Y, et al. Association between clinicopathological features and programmed death ligand expression in non-small cell lung cancer. Anticancer Res 2018; 38: 1077-1083.
46.
Wang H, Agulnik A, Kasymjanova G, Wang A, Jiménez P, Cohen V, et al. Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. Ann Oncol 2018; 29: 1217-1222.
47.
Russell-Goldman E, Kravets S, Dahlberg ES, Sholl LM, Vive-ro M. Cytologic-histologic correlation of programmed death- ligand 1 immunohistochemistry in lung carcinomas. Cancer Cytopathol 2018; 126: 253-256.
48.
Gompelmann D, Sarova P, Mosleh B, Papaporfyriou A, Oberndorfer F, Idzko M, et al. PD-L1 assessment in lung cancer biopsies – pitfalls and limitations. Int J Biol Markers 2024; 39: 3-8.
49.
Mansour MSI, Malmros K, Mager U, Lindquist KE, Hejny K, Holmgren B, et al. PD-L1 expression in non-small cell lung cancer specimens: association with clinicopathological factors and molecular alterations. Int J Mol Sci 2022; 23: 4517.
50.
Ilie M, Long-Mira E, Bence C, Butori C, Lassalle S, Bouhlel L, et al. Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies. Ann Oncol 2016; 27: 147-153.
Share
RELATED ARTICLE
| eISSN: | 2084-9869 |
| ISSN: | 1233-9687 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
